Ascendis Pharma A/S (NASDAQ:ASND) is set to announce its earnings results after the market closes on Monday, November 18th. Analysts expect the company to announce earnings of ($1.37) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, August 28th. The biotechnology company reported ($1.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.08). The business had revenue of $3.61 million during the quarter, compared to the consensus estimate of $0.68 million. Ascendis Pharma A/S had a negative net margin of 932.52% and a negative return on equity of 35.99%. On average, analysts expect Ascendis Pharma A/S to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Shares of Ascendis Pharma A/S stock opened at $113.45 on Monday. The stock’s fifty day moving average is $102.22 and its two-hundred day moving average is $112.94. The company has a market capitalization of $4.82 billion, a PE ratio of -30.33 and a beta of 0.63. The company has a quick ratio of 11.59, a current ratio of 11.59 and a debt-to-equity ratio of 0.05. Ascendis Pharma A/S has a 52 week low of $53.21 and a 52 week high of $133.96.

Several equities analysts have commented on ASND shares. JPMorgan Chase & Co. upped their price objective on Ascendis Pharma A/S from $143.00 to $152.00 and gave the company an “overweight” rating in a research report on Thursday, August 29th. Zacks Investment Research raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating and set a $118.00 price objective on the stock in a research report on Tuesday, October 29th. ValuEngine raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. BidaskClub downgraded Ascendis Pharma A/S from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 12th. Finally, Wedbush cut their price objective on Ascendis Pharma A/S from $191.00 to $186.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. Ascendis Pharma A/S has an average rating of “Buy” and an average target price of $142.75.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Further Reading: Commodities

Earnings History for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.